Westfield Capital Management
RETA

Westfield Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Westfield Capital Management’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-158,746
Closed -$24.8M – 260
2020
Q2 		$24.8M Sell
158,746
-44,803
-22% -$6.81M 0.17% 153
2020
Q1 		$29.4M Buy
203,549
+67,184
+49% +$13M 0.26% 116
2019
Q4 		$27.9M Buy
+136,365
New +$24.9M 0.2% 139

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Westfield Capital Management's RETA Position: Q3 2020 in Review

Westfield Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2020, closing a stake of 158,746 shares — an estimated $24.8M sold.

Westfield Capital Management first reported a position in RETA in Q4 2019 and held it in 3 quarters. The position peaked at $29.4M in Q1 2020. 186 funds tracked by Wall St. Rank hold RETA as of Q3 2020.

  • Westfield Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2020 after selling out during the quarter.
  • Westfield Capital Management sold 158,746 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2020, an estimated $24.8M.
  • Westfield Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2019 and held it in 3 quarters.
  • Westfield Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $29.4M in Q1 2020.
  • 186 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2020.

Based on Westfield Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.